AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Cresco Labs Inc.
Video analysis: CRLBF
All videosNo video analysis for this stock yet. Request one from our team.
News: CRLBF
Cannabis Stock CRLBF Surges 10% in a Month: Time to Buy or Sell?
Cresco's 10% monthly rally reflects stronger revenues, organic growth and margins, but competition and normalization risks cloud the outlook.
Cresco Labs Acquires Nine Pennsylvania Dispensaries in Accretive Transaction to Strengthen Market Leadership
CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) (“Cresco Labs” or the “Company”) today announced the closing of its acquisition of 100% of the outstanding equity interests in PharmaCann Penn, LLC (“PharmaCann”) for an aggregate consideration of US$50 million (the “Transaction”). The Transaction consists of nine operational retail medical marijuana dispensaries in Pennsylvania, advancing Cresco's leadership position in the second-largest medical marijuana market, wh.
3 Marijuana Stocks For Investors To Consider
What will help marijuana stock investors trade more, even in the midst of laws changing in the USA? It is no secret that nothing has moved pot stocks more than news of global reform or regulatory matters. For the US, what happens at the federal level has moved the needle the most, with the recent passing of legislation to reclassify cannabis to Schedule 3.
Cresco Labs Inc. (CRLBF) Q2 2026 Earnings Call Transcript
Cresco Labs Inc. (CRLBF) Q2 2026 Earnings Call Transcript
Cresco Labs Inc. (CRLBF) Q2 Earnings and Revenues Top Estimates
Cresco Labs Inc. (CRLBF) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to a loss of $0.05 per share a year ago.
Cresco Labs Reports Second Quarter 2026 Financial Results; Delivers $173 Million in Revenue and $40 Million in Adjusted EBITDA
CHICAGO--(BUSINESS WIRE)--Cresco Labs Reports Second Quarter 2026 Financial Results; Delivers $173 Million in Revenue and $40 Million in Adjusted EBITDA.
Cresco Labs to Report Second Quarter 2026 Financial Results on August 6, 2026
CHICAGO--(BUSINESS WIRE)--Cresco Labs Inc. (CSE:CL) (OTCQX:CRLBF) (FSE: 6CQ) (“Cresco” or “Company”), the industry leader in branded cannabis products with a portfolio of America's most popular brands and the operator of Sunnyside dispensaries, today announced it will report financial results for the quarter ended June 30th, 2026 on Thursday, August 6, 2026 before the market opens. The Company will host a conference call and webcast to discuss its financial results and provide investors with ke.
Looking for Cannabis Growth? Watch These 3 Marijuana Stocks in July 2026
The cannabis industry continues evolving as operators focus on profitability, stronger balance sheets, and strategic expansion. At the same time, federal cannabis reform discussions have improved investor sentiment. Many companies are also positioning themselves for future regulatory changes. As a result, investors are paying closer attention to established multi-state operators with recognizable brands and expanding retail footprints.
